Cargando…

Reduced osteoprotegerin expression by osteocytes may contribute to rebound resorption after denosumab discontinuation

Denosumab is an anti-RANKL Ab that potently suppresses bone resorption, increases bone mass, and reduces fracture risk. Discontinuation of denosumab causes rapid rebound bone resorption and bone loss, but the molecular mechanisms are unclear. We generated humanized RANKL mice and treated them with d...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fu, Qiang, Bustamante-Gomez, Nancy C., Reyes-Pardo, Humberto, Gubrij, Igor, Escalona-Vargas, Diana, Thostenson, Jeff D., Palmieri, Michela, Goellner, Joseph J., Nookaew, Intawat, Barnes, C. Lowry, Stambough, Jeffrey B., Ambrogini, Elena, O’Brien, Charles A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2023
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10561722/ https://www.ncbi.nlm.nih.gov/pubmed/37581932 http://dx.doi.org/10.1172/jci.insight.167790

Ejemplares similares

Local Production of Osteoprotegerin by Osteoblasts Suppresses Bone Resorption
por: Cawley, Keisha M., et al.
Publicado: (2020)

Denosumab Discontinuation and the Rebound Phenomenon: A Narrative Review
por: Anastasilakis, Athanasios D., et al.
Publicado: (2021)

Osteoclast Recycling and the Rebound Phenomenon Following Denosumab Discontinuation
por: Kim, Albert S., et al.
Publicado: (2022)

Symptomatic Rebound Hypercalcemia After Denosumab Discontinuation in a Pediatric Patient With Cherubism
por: Marpuri, Ian, et al.
Publicado: (2021)

Elevated Bone Hardness Under Denosumab Treatment, With Persisting Lower Osteocyte Viability During Discontinuation
por: Jähn-Rickert, Katharina, et al.
Publicado: (2020)

Rebound-associated vertebral fractures after denosumab discontinuation in a lung cancer patient with bone metastases
por: Dupont, Jolan, et al.
Publicado: (2022)

Rebound Vertebral Fractures in a Patient With Lung Cancer After Oncology-Dose Denosumab Discontinuation: A Cautionary Tale
por: Tyan, Alexander, et al.
Publicado: (2019)

Similarities and Differences in the Management of Patients with Osteoporotic Vertebral Fractures and Those with Rebound-Associated Vertebral Fractures Following Discontinuation of Denosumab
por: Anastasilakis, Athanasios D., et al.
Publicado: (2023)

Rebound Hypercalcemia After Denosumab Therapy in a Child With Cherubism
por: Litao, Melissa Kaori S, et al.
Publicado: (2021)

Rebound-associated vertebral fractures may occur in sequential time points following denosumab discontinuation: need for prompt treatment re-initiation
por: Anastasilakis, Athanasios D., et al.
Publicado: (2020)

Preventing Rebound-Associated Fractures after Discontinuation of Denosumab Therapy: A Position Statement from the Health Insurance Committee of the Korean Endocrine Society
por: Kim, Bu Kyung, et al.
Publicado: (2021)

Osteocyte-Related Cytokines Regulate Osteoclast Formation and Bone Resorption
por: Kitaura, Hideki, et al.
Publicado: (2020)

Denosumab-Induced Rebound Hypercalcemia Treated With Bisphosphonates in a Pediatric Patient
por: Gandolfi, Anne, et al.
Publicado: (2023)

Effect of risedronate on bone loss at discontinuation of denosumab
por: Laroche, Michel, et al.
Publicado: (2020)

Bone Health and Denosumab Discontinuation in Oncology Populations
por: Cheung, Yee-Ming Melody, et al.
Publicado: (2022)

Effective CRISPR interference of an endogenous gene via a single transgene in mice
por: MacLeod, Ryan S., et al.
Publicado: (2019)

The Role of Bisphosphonates Prior to Denosumab Treatment on Rebound Fractures: A Mini Review
por: Inojosa, Arthur Costa, et al.
Publicado: (2022)

Mechanically-Loaded Breast Cancer Cells Modify Osteocyte Mechanosensitivity by Secreting Factors That Increase Osteocyte Dendrite Formation and Downstream Resorption
por: Wang, Wenbo, et al.
Publicado: (2018)

Observations following discontinuation of long-term denosumab therapy
por: McClung, M. R., et al.
Publicado: (2017)

Denosumab mimics the natural decoy receptor osteoprotegerin by interacting with its major binding site on RANKL
por: Schieferdecker, Aneta, et al.
Publicado: (2014)

Rebound-Associated Vertebral Fractures Two Months After a Missed Dose of Denosumab
por: Caseja, Ahl Jeffrey, et al.
Publicado: (2021)

Osteocyte apoptosis: the roles and key molecular mechanisms in resorption-related bone diseases
por: Ru, Jiang-ying, et al.
Publicado: (2020)

Scl-Ab reverts pro-osteoclastogenic signalling and resorption in estrogen deficient osteocytes
por: Allison, H., et al.
Publicado: (2020)

Sympathetic Innervation Regulates Osteocyte‐Mediated Cortical Bone Resorption during Lactation
por: Guo, Qiaoyue, et al.
Publicado: (2023)

Hypercalcemia following discontinuation of denosumab therapy: A systematic review
por: Horiuchi, Keisuke, et al.
Publicado: (2021)

Discontinuing Denosumab: Can It Be Done Safely? A Review of the Literature
por: Tay, Wei Lin, et al.
Publicado: (2022)

The Effect of Discontinuing Denosumab in Patients With Rheumatoid Arthritis Treated With Glucocorticoids
por: Saag, Kenneth G., et al.
Publicado: (2022)

The Efficacy of Denosumab in the Management of a Tibial Paediatric Aneurysmal Bone Cyst Compromised by Rebound Hypercalcaemia
por: Harcus, Matthew, et al.
Publicado: (2020)

Therapeutic targeting of osteoclasts by osteoprotegerin and bisphosphonates leads to a reduction of TNFalpha-mediated bone resorption
por: Redlich, K, et al.
Publicado: (2001)

Osteoprotegerin reduces osteoclast resorption activity without affecting osteogenesis on nanoparticulate mineralized collagen scaffolds
por: Ren, Xiaoyan, et al.
Publicado: (2019)

Catastrophic outcome of patients with a rebound after Natalizumab treatment discontinuation
por: González‐Suarez, Inés, et al.
Publicado: (2017)

Notch3 signaling between myeloma cells and osteocytes in the tumor niche promotes tumor growth and bone destruction
por: Sabol, Hayley M., et al.
Publicado: (2022)

OR27-02 The Bone Anabolic Effect Of An Antibody Blocking Oxidized Phospholipids Is Associated With An Increase In Wnt10b In Osteoblasts.
por: Palmieri, Michela, et al.
Publicado: (2023)

An Acid‐Activatable Fluorescence Probe for Imaging Osteocytic Bone Resorption Activity in Deep Bone Cavities
por: Hashimoto, Ryu, et al.
Publicado: (2020)

Fractures After Denosumab Discontinuation: A Retrospective Study of 797 Cases
por: Burckhardt, Peter, et al.
Publicado: (2021)

IGF-I increases markers of osteoblastic activity and reduces bone resorption via osteoprotegerin and RANK-ligand
por: Guerra-Menéndez, Lucia, et al.
Publicado: (2013)

Virological and clinical rebounds of COVID-19 soon after nirmatrelvir/ritonavir discontinuation
por: Antonelli, Guido, et al.
Publicado: (2022)

Low bone mass and changes in the osteocyte network in mice lacking autophagy in the osteoblast lineage
por: Piemontese, Marilina, et al.
Publicado: (2016)

To rebound or not to rebound
por: Stahl, Bethany A, et al.
Publicado: (2017)

SAT-532 Bisphosphonates Prevent Bone Loss Associated with Denosumab Treatment Discontinuation
por: Zanchetta, Maria Belen, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_f2d7k6apre33bmtbof8r2bp01d